Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Johannes Hasskamp, Christian Meinhardt, Antje Timmer
https://pubmed.ncbi.nlm.nih.gov/40357993/Actively Recruiting
Led by University of Calgary · Updated on 2026-10-26
210
Participants Needed
23
Research Sites
74 weeks
Total Duration
Researchers are evaluating three classes of biologic treatments for patients with moderate-to-severe Crohns disease that primarily affects the small bowel ileal-dominant. The study aims to find which biologic class leads to the highest number of patients achieving endoscopic remissionmeaning healed ulcers in the small bowelwithout needing corticosteroids after one year. All treatments used are approved by Health Canada and are studied in a real-world setting. Participants will be randomly assigned to one of three treatment groups at the start of the study a TNF antagonist infliximab or adalimumab, an anti-integrin agent vedolizumab, or an anti-IL23 targeted agent ustekinumab or risankizumab. These treatments are given according to standard care schedules using intravenous or subcutaneous administration at specific weeks and intervals during the study. Participants who are on corticosteroids will begin tapering off these within six weeks of starting their biologic therapy. During the study, participants will undergo evaluations at months 4, 8, and 12, including assessments using the Harvey Bradshaw Index HBI and EuroQOL 5-domain questionnaire EQ-5D, and tests for C-reactive protein and fecal calprotectin levels. At 12 months, a video-recorded ileocolonoscopy will determine if endoscopic remission has been achieved. The study will also monitor clinical remission, treatment persistence, safety, and quality of life over the one-year period.
CONDITIONS
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
H
Harsha Ashton
C
Christopher Ma, MD MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Calgary
Lead Sponsor
Alimentiv Inc.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 3 months before randomization
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive one of three biologic treatment strategies as part of their routine care, including TNF antagonists, anti-integrin agents, or anti-IL23 targeted therapies.
Regular visits and assessments at months 4, 8, and 12
Duration - At months 4, 8, and 12
Participants undergo evaluations including clinical indices, quality of life questionnaires, inflammatory marker tests, and a video-recorded ileocolonoscopy to assess healing and remission.
3 visits for clinical and laboratory assessments; 1 ileocolonoscopy at month 12
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Johannes Hasskamp, Christian Meinhardt, Antje Timmer
https://pubmed.ncbi.nlm.nih.gov/40357993/University of Calgary
Lead Sponsor
Alimentiv Inc.
Collaborating Sponsor